<DOC>
	<DOCNO>NCT00192088</DOCNO>
	<brief_summary>Open label single arm phase II study Pemetrexed plus Oxaliplatin patient advance gastric carcinoma previously treat palliative chemotherapy . 43 Patients enrol local trial . The primary objective study determine response rate treatment.Schedule study follow : 6 cycles/21 day Pemetrexed 500 mg/m2 follow Oxaliplatin 120 mg/m2 . This study also include pharmacogenomic pharmacogenetic investigation order ass determinant efficacy toxicity treatment Pemetrexed Oxaliplatin study population .</brief_summary>
	<brief_title>A Study Pemetrexed Plus Oxaliplatin First Line Therapy Advanced Gastric Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion Criteria Histologically proven diagnosis adenocarcinoma stomach ( include adenocarcinoma gastroesophageal junction ) Stage IIIB Stage IV disease , accord American Joint Committee Cancer criterion , amenable curative surgery radiation Disease status must least one measurable disease define RECIST criterion . Performance Status 2 ECOG Scale . Adequate organ function include follow : Bone marrow : absolute neutrophil count ( ANC ) &gt; equal 1.5 * 109/L , platelet &gt; equal 100 *109/L , hemoglobin &gt; equal 10 g/dL . Hepatic : bilirubin &lt; equal 1.5 x ULN ; alkaline phosphatase , aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; equal 3 x ULN ( alkaline phosphatase , AST , ALT minor equal 5 x ULN acceptable liver tumor involvement ) , serum albumin &gt; equal to3g/dL . Renal : Calculated creatinine clearance major equal 45 ml/min ( use standard CockcroftGault formula ) . Exclusion Criteria No Prior palliative chemotherapy advance disease Previous radiation therapy allow limited must include whole pelvis radiation . Patients must recover toxic effect treatment prior study enrollment ( except alopecia ) . Prior radiotherapy must complete least 30 day study enrollment Known suspect brain metastasis Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin malignancy treat least 5 year previously evidence recurrence ) Inability interrupt aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day , day , 2 day dose pemetrexed plus oxaliplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>